These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 32060030)
41. Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database. Durrieu G; Maupiler M; Rousseau V; Chebane L; Montastruc F; Bondon-Guitton E; Montastruc JL Paediatr Drugs; 2018 Feb; 20(1):81-87. PubMed ID: 28766184 [TBL] [Abstract][Full Text] [Related]
42. Collaboration between patient and pharmacovigilance organizations to gain insight into adults' experiences with drug use and ADRs for the treatment of ADHD. Weits G; Härmark L; Hartman J; Kant A Expert Opin Drug Saf; 2019 Apr; 18(4):333-337. PubMed ID: 30845849 [TBL] [Abstract][Full Text] [Related]
43. Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports. Blake KV; Saint-Raymond A; Zaccaria C; Domergue F; Pelle B; Slattery J Paediatr Drugs; 2016 Feb; 18(1):55-63. PubMed ID: 26597489 [TBL] [Abstract][Full Text] [Related]
44. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center]. Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165 [TBL] [Abstract][Full Text] [Related]
45. Time to onset in statistical signal detection revisited: A follow-up study in long-term onset adverse drug reactions. Scholl JHG; van Hunsel FPAM; Hak E; van Puijenbroek EP Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1283-1289. PubMed ID: 31189217 [TBL] [Abstract][Full Text] [Related]
46. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa. Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970 [TBL] [Abstract][Full Text] [Related]
47. Adverse drug reactions to self-medication: a study in a pharmacovigilance database. Berreni A; Montastruc F; Bondon-Guitton E; Rousseau V; Abadie D; Durrieu G; Chebane L; Giroud JP; Bagheri H; Montastruc JL Fundam Clin Pharmacol; 2015 Oct; 29(5):517-20. PubMed ID: 26215671 [TBL] [Abstract][Full Text] [Related]
48. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055 [TBL] [Abstract][Full Text] [Related]
49. Pediatric pharmacovigilance in an institute of national importance: Journey has just begun. Sharma PK; Misra AK; Gupta N; Khera D; Gupta A; Khera P Indian J Pharmacol; 2017; 49(5):390-395. PubMed ID: 29515280 [TBL] [Abstract][Full Text] [Related]
50. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics. Minjon L; van den Ban E; de Jong E; Souverein PC; Egberts TCG; Heerdink ER J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):124-132. PubMed ID: 30676073 [TBL] [Abstract][Full Text] [Related]
51. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database. Kaguelidou F; Beau-Salinas F; Jonville-Bera AP; Jacqz-Aigrain E Br J Clin Pharmacol; 2016 Oct; 82(4):1058-68. PubMed ID: 27276109 [TBL] [Abstract][Full Text] [Related]
52. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection. de Bie S; Verhamme KM; Straus SM; Stricker BH; Sturkenboom MC Drug Saf; 2012 Apr; 35(4):335-46. PubMed ID: 22435344 [TBL] [Abstract][Full Text] [Related]
53. Identification of discrepancies between adverse drug reactions coded by medical records technicians and those reported by the pharmacovigilance team in pediatrics: An intervention to improve identification, reporting, and coding. Soyer J; Necsoiu D; Desjardins I; Lebel D; Bussières JF Arch Pediatr; 2019 Oct; 26(7):400-406. PubMed ID: 31611146 [TBL] [Abstract][Full Text] [Related]
54. Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases. Machado-Alba JE; Londoño-Builes MJ; Echeverri-Cataño LF; Ochoa-Orozco SA Biomedica; 2016 Mar; 36(1):59-66. PubMed ID: 27622439 [TBL] [Abstract][Full Text] [Related]
55. Adverse drug reactions in infants, children and adolescents exposed to antidepressants: a French pharmacovigilance study. Barthez S; Revet A; Chouchana L; Jonville-Bera AP; Pizzoglio V; Raynaud JP; Chebane L; Lapeyre-Mestre M; Montastruc F Eur J Clin Pharmacol; 2020 Nov; 76(11):1591-1599. PubMed ID: 32588107 [TBL] [Abstract][Full Text] [Related]
56. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. Lombardi N; Crescioli G; Bettiol A; Marconi E; Vitiello A; Bonaiuti R; Calvani AM; Masi S; Lucenteforte E; Mugelli A; Giovannelli L; Vannacci A BMC Pharmacol Toxicol; 2018 Apr; 19(1):16. PubMed ID: 29661234 [TBL] [Abstract][Full Text] [Related]
57. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554 [TBL] [Abstract][Full Text] [Related]
58. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683 [TBL] [Abstract][Full Text] [Related]
59. Are non-serious adverse reactions to psychiatric drugs really non-serious? Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186 [TBL] [Abstract][Full Text] [Related]
60. Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study. Campillo JT; Eiden C; Boussinesq M; Pion SDS; Faillie JL; Chesnais CB Br J Clin Pharmacol; 2022 Mar; 88(3):1094-1106. PubMed ID: 34390273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]